Medexus Pharmaceuticals - PDDPF Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.27
▼ -0.11 (-4.62%)

This chart shows the closing price for PDDPF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Medexus Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PDDPF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PDDPF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Medexus Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.27.

This chart shows the closing price for PDDPF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Medexus Pharmaceuticals. This rating has held steady since July 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/24/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/19/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/20/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/19/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/13/2020Stifel NicolausBoost TargetBuy$7.00 ➝ $7.25
(Data available from 8/18/2017 forward)

News Sentiment Rating

0.62 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/20/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/19/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/21/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/20/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/20/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/19/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/19/2022
  • 4 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/18/2022

Current Sentiment

  • 4 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Medexus Pharmaceuticals logo
Medexus Pharmaceuticals, Inc. operates as a pharmaceutical company. It provide healthcare products to Healthcare Professionals and patients and focuses on therapeutic areas of auto-immune disease and pediatrics. The company products include Rasuvo, Metoject and Rupall. Medexus was founded by Sylvain Chretien in January 2008 and is headquartered in Verdun, Canada.
Read More

Today's Range

Now: $2.27
Low: $2.00
High: $2.37

50 Day Range

MA: $3.01
Low: $1.78
High: $3.22

52 Week Range

Now: $2.27
Low: $1.70
High: $3.99

Volume

24,986 shs

Average Volume

4,355 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Medexus Pharmaceuticals?

The following equities research analysts have issued reports on Medexus Pharmaceuticals in the last twelve months:
View the latest analyst ratings for PDDPF.

What is the current price target for Medexus Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Medexus Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Medexus Pharmaceuticals in the next year.
View the latest price targets for PDDPF.

What is the current consensus analyst rating for Medexus Pharmaceuticals?

Medexus Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for PDDPF.

What other companies compete with Medexus Pharmaceuticals?

How do I contact Medexus Pharmaceuticals' investor relations team?

The company's listed phone number is (514) 762-2626. The official website for Medexus Pharmaceuticals is www.medexus.com. Learn More about contacing Medexus Pharmaceuticals investor relations.